Fed. Circ. Won't Rethink IP Safe Harbor Case

By Lauren Berg

The Federal Circuit on Wednesday declined to review its decision affirming the dismissal of Edwards Lifesciences' infringement suit against Meril Life Sciences after Edwards urged the full court to narrow its interpretation of a U.S. Food and Drug Administration safe harbor that essentially allows patent infringement during drug development.

 Order attached | Read full article » | Save to favorites »